# Anna Fang

> Anna Fang is a seed investor at ZhenFund (Beijing) backing Biotechnology and Consulting. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ZhenFund](https://shizune.co/investors/profile/zhenfund)
- Location: Beijing, China
- Total investments: 3
- Last investment: Sep 2022
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/anna-fang-a2a07441
- Website: http://zhenfund.com

Anna Fang is a seed investor at ZhenFund in Beijing focused on Biotechnology and Consulting. Anna Fang is based out of Beijing, Beijing and is the Founding Partner of ZhenFund. Anna previously worked at J.P. Morgan as a Investment Banking Analyst. Anna Fang attended the Stanford University and Columbia University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Consulting | 1 | 33% |
| Agriculture | 1 | 33% |
| Therapeutics | 1 | 33% |
| Food and Beverage | 1 | 33% |

6 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Meliora Therapeutics | Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications. | $11M | Seed | Sep 29, 2022 |  |
| Meliora Therapeutics | Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications. | $11M | Seed | Sep 29, 2022 |  |
| CellX | CellX is creating the world's first mushroom protein from morel mycelium fermentation. Our ingredient and product solutions can be applied to savory snacks, protein powders, and meat alternatives.We are also licensing existing IPs to help accelerate the commercialization of cultivated meat. Our technology offerings include suspension celllines and serum-free media that have achieved 30M/ml cell density and <$5/L media cost, tested at the 2,000L scale. | $4.3M | Seed | Mar 15, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [BrightEdge Fund](https://shizune.co/investors/profile/brightedge-fund) — VC Fund, 3 deals together
- [Axial VC](https://shizune.co/investors/profile/axial-vc) — VC Fund, 2 deals together
- [HOF Capital](https://shizune.co/investors/profile/hof-capital) — VC Fund, 2 deals together
- [Obvious Ventures](https://shizune.co/investors/profile/obvious-ventures) — VC Fund, 2 deals together
- [Pebblebed](https://shizune.co/investors/profile/pebblebed) — VC Fund, 2 deals together
- [Village Global](https://shizune.co/investors/profile/village-global-2) — VC Fund, 2 deals together

## About ZhenFund

VC Fund · Beijing, China

ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.

5 contacts available at ZhenFund.

| Name | Title | Profile |
| --- | --- | --- |
| Bob Xiaoping Xu | Founding Partner | https://shizune.co/investors/profile/bob-xu-3 |
| Emma Yin | Partner | https://shizune.co/investors/profile/emma-yin |
| Tianyi Qin | Principal | https://shizune.co/investors/profile/tianyi-qin |
| Anna Fang | Founding Partner | https://shizune.co/investors/profile/anna-fang |
| Cyriac Roeding | Limited Investor | https://shizune.co/investors/profile/cyriac-roeding |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Anna Fang invest in?

Anna Fang invests primarily in Biotechnology, Consulting and Agriculture startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Anna Fang last invest?

The most recent investment recorded for Anna Fang closed in Sep 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co